By Jonathan Stempel
(Reuters) - A federal appeals court on Wednesday threw out an order requiring AbbVie Inc <ABBV.N> and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.
Ruling in an antitrust case by the Federal Trade Commission, the 3rd U.S. Circuit Court of Appeals in Philadelphia said the lower court judge who ordered the disgorgement by AbbVie and Besins Healthcare Inc lacked authority under federal law.
But in a 94-page decision, Circuit Judge Thomas Hardiman also said the lower court judge correctly found AbbVie and privately-held Besins liable for monopolization for filing a sham, "objectively baseless" patent infringement lawsuit in 2011 against Perrigo Co <PRGO.N> to delay generic AndroGel.
Hardiman also reinstated an FTC claim challenging AbbVie's agreement to drop a similar lawsuit against Teva Pharmaceutical Industries Ltd <TEVA.TA> while letting the Israeli drugmaker sell a generic version of its TriCor cholesterol drug.
The FTC called that arrangement an illegal "reverse payment," where the billions of dollars of AndroGel revenue that AbbVie wanted to protect far offset the $100 million in TriCor sales it might sacrifice.
Both patent lawsuits had been brought by Abbott Laboratories, which split off North Chicago, Illinois-based AbbVie at the start of 2013.
The FTC case is part of that regulator's long fight against "pay for delay" settlements, where brand-name drugmakers pay rivals to postpone cheaper generics in exchange for resolving patent lawsuits.
Wednesday's 3-0 decision returned the case to U.S. District Judge Harvey Bartle in Philadelphia.
An FTC spokeswoman said the regulator was pleased the reverse payment claim was reinstated, was disappointed with parts of the decision, and will consider its legal options.
AbbVie and lawyers for Besins did not respond to requests for comment. Teva is no longer a defendant.
Annual U.S. net sales for AndroGel sometimes topped $1 billion before generic versions entered the U.S. market in 2015.
The case is Federal Trade Commission v AbbVie Inc et al, 3rd U.S. Circuit Court of Appeals, No. 18-2748.
(Reporting by Jonathan Stempel in New York; Editing by Bernadette Baum and David Gregorio)